• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CLOMIPRAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CLOMIPRAMINE chembl:CHEMBL415 Approved

    Alternate Names:

    NSC-169865
    ANAFRANIL
    CLOMIPRAMINE
    CHLORIMIPRAMINE
    3-(3-CHLORO-10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYL-1-PROPANAMINE
    G 34586
    MONOCHLORIMIPRAMINE
    3-CHLOROIMIPRAMINE
    3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE
    CLOMIPRAMINA
    ANAFRANIL®
    ANA586
    G-34586
    CLOMIPRAMINUM
    chembl:CHEMBL415
    rxcui:2597
    drugbank:01242
    pubchem.compound:2801
    chemidplus:303-49-1

    Drug Info:

    FDA Approval 1989
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class antidepressive agents, tricyclic
    Year of Approval 1989
    (3 More Sources)

    Publications:

    Whale R et al., 2000, Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine., Psychopharmacology (Berl)
    Gillman, 2007, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated., Br. J. Pharmacol.
    Borkowska et al., [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]., Psychiatr. Pol.
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Suhara et al., 2003, High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography., Arch. Gen. Psychiatry
    Malizia et al., 1997, Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo., J. Psychopharmacol. (Oxford)
    Alvarez et al., 1999, Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine., Clin. Pharmacol. Ther.
    Larsen et al., 2004, Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects., Br. J. Pharmacol.
    Jungkun et al., 2001, Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans., J Neural Transm (Vienna)
    Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem
    Antoniazzi S et al., 2017, The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report., J Clin Pharm Ther
    Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
    Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
    Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
    Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
    Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
  • CLOMIPRAMINE   FKBP5

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21449676 20709156 19676097 18597649 17467808 15565110


    Sources:
    PharmGKB

  • CLOMIPRAMINE   SLC6A4

    Interaction Score: 1.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10867985 17471183 12647451 9537821 12695316 9305421 10613618 14993096


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • CLOMIPRAMINE   SLC6A2

    Interaction Score: 0.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    9537821 11341486


    Sources:
    TdgClinicalTrial TEND

  • CLOMIPRAMINE   HTR1B

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21449676


    Sources:
    PharmGKB

  • CLOMIPRAMINE   SCN5A

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26372073


    Sources:
    DTC

  • CLOMIPRAMINE   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21449676


    Sources:
    PharmGKB

  • CLOMIPRAMINE   PPARD

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLOMIPRAMINE   DRD1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLOMIPRAMINE   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27800629


    Sources:
    DTC PharmGKB

  • CLOMIPRAMINE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC FDA

  • CLOMIPRAMINE   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLOMIPRAMINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • TEND: CLOMIPRAMINE

    • Version: 01-August-2011

    Alternate Names:
    CLOMIPRAMINE Primary Drug Name

    Drug Info:
    Year of Approval 1989
    Drug Class antidepressive agents, tricyclic

    Publications:

  • TdgClinicalTrial: CLOMIPRAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class small molecule
    FDA Approval 1989

    Publications:

  • DTC: CLOMIPRAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL415 ChEMBL Drug ID

    Drug Info:

    Publications:
    Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem

  • PharmGKB: clomipramine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
    Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics

  • TTD: Clomipramine

    • Version: 2020.06.01

    Alternate Names:
    D0ZS8P TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL415

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Clomipramine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21